Phase I study of amrubicin plus cisplatin and concurrent accelerated hyperfractionated thoracic radiotherapy for limited‐disease small cell lung cancer: protocol of ACIST study

BACKGROUND: Etoposide plus cisplatin (EP) combined with concurrent accelerated hyperfractionated thoracic radiotherapy (AHTRT) is the standard treatment strategy for unresectable limited‐disease (LD) small cell lung cancer (SCLC), which has remained unchanged for over two decades. Based on a previou...

Descripción completa

Detalles Bibliográficos
Autores principales: Akagi, Kazumasa, Taniguchi, Hirokazu, Fukuda, Minoru, Yamazaki, Takuya, Ono, Sawana, Tomono, Hiromi, Suyama, Takayuki, Shimada, Midori, Gyotoku, Hiroshi, Takemoto, Shinnosuke, Yamaguchi, Hiroyuki, Dotsu, Yosuke, Senju, Hiroaki, Soda, Hiroshi, Mizowaki, Takashi, Monzen, Yoshio, Ikeda, Takaya, Nagashima, Seiji, Tasaki, Yutaro, Nakamura, Daisuke, Komiya, Kazutoshi, Nakatomi, Katsumi, Sasaki, Eisuke, Hirakawa, Koichi, Mukae, Hiroshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2022
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9376170/
https://www.ncbi.nlm.nih.gov/pubmed/35808894
http://dx.doi.org/10.1111/1759-7714.14555

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9376170/
https://www.ncbi.nlm.nih.gov/pubmed/35808894
http://dx.doi.org/10.1111/1759-7714.14555

Ejemplares similares